The clinical observation of serum specific biomarkers in patients with chronic graft-versus-host disease.
10.3760/cma.j.issn.0253-2727.2019.11.012
- Author:
Ting CHEN
1
;
Xiao Ping LI
;
Cheng ZHANG
;
Pei Yan KONG
;
Qiang Guo GAO
;
Lun TANG
;
Rui WANG
;
Shi Jie YANG
;
Lei GAO
;
Yao LIU
;
Li GAO
;
Yi Mei FENG
;
Jun RAO
;
Xian Gui PENG
;
Xi ZHANG
Author Information
1. Medical Center of Hematology, Xinqiao Hospital of Army Medical University, State Key Laboratory of Trauma, Burns and Combined Injury, Chongqing 400037, China.
- Publication Type:Journal Article
- Keywords:
Allogeneic hematopoietic stem cell transplantation;
Chronic graft versus host disease;
Serum biomarkers
- MeSH:
Biomarkers;
Chronic Disease;
Graft vs Host Disease;
Hematopoietic Stem Cell Transplantation;
Humans;
Transplantation, Homologous
- From:
Chinese Journal of Hematology
2019;40(11):948-952
- CountryChina
- Language:Chinese
-
Abstract:
Objective: Chronic graft-versus-host disease (cGVHD) is a major long-term complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) . It is important to study the changes of serum biomarkers expression in patients for early diagnosis and treatment. Methods: The expression levels of five serum protein markers (IL-1b, IL-16, CXCL9, CCL19, CCL17) in patients with or without cGVHD after allo-HSCT were detected by liquid suspension microarray. Results: Compared with the control group without cGVHD, the expression levels of CXCL9 and CCL17 in serum of patients with cGVHD were significantly increased (P<0.05) . CCL17 was correlated with the severity of cGVHD (P<0.001) . CXCL9 was significantly increased in the serum of patients with skin lesion (P<0.01) , and CCL17 was significantly expressed in cGVHD patients with liver as the target organ (P<0.01) . Conclusion: The combination of CXCL9 and CCL17 can be used as serum biomarkers of cGVHD, which has certain reference value in assisting the diagnosis and evaluation of cGVHD severity.
